# NANT 2021-01 Phase II STING (Sequential Temozolomide, Irinotecan, NK Cells and GD2 mAb) Trial

> **NCT06450041** · PHASE2 · RECRUITING · sponsor: **New Approaches to Neuroblastoma Therapy Consortium** · enrollment: 62 (estimated)

## Conditions studied

- Neuroblastoma

## Interventions

- **DRUG:** Universal Donor (UD) TGFβi NK Cells
- **DRUG:** Temozolomide
- **DRUG:** Irinotecan
- **DRUG:** Dinutuximab
- **DRUG:** GM-CSF

## Key facts

- **NCT ID:** NCT06450041
- **Lead sponsor:** New Approaches to Neuroblastoma Therapy Consortium
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-12-16
- **Primary completion:** 2028-12
- **Final completion:** 2038-12
- **Target enrollment:** 62 (ESTIMATED)
- **Last updated:** 2026-03-23

## Collaborators

- Nationwide Children's Hospital
- United Therapeutics
- Children's Neuroblastoma Cancer Fund

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06450041

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06450041, "NANT 2021-01 Phase II STING (Sequential Temozolomide, Irinotecan, NK Cells and GD2 mAb) Trial". Retrieved via AI Analytics 2026-07-02 from https://api.ai-analytics.org/clinical/NCT06450041. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*